ArriVent BioPharma (AVBP) Stock: Buy, Sell, or Hold?
AVBP - ArriVent BioPharma, Inc. Common Stock
$19.20
0.08 (0.42%)
â˛
5d:
+14.35%
30d:
-36.63%
90d:
-39.49%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 09, 2026
16d
Get Alerted When AVBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: AVBP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: AVBP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: AVBP is currently trading at $19.20, which is considered slightly low relative to its 30-day fair value range of $17.81 to $29.95.
Technical Outlook: Technically, AVBP is in a strong downtrend. The price is approaching resistance at $19.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AVBP scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $22.30 (+16.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AVBP is in a strong downtrend. The price is approaching resistance at $19.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AVBP scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $22.30 (+16.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$17.81 -
$29.95
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
92.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($22.30)
- WARNING: Composite score 53/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$17.81 -
$29.95
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$15.26
Resistance Level
$19.68
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.89
Wall Street Target
$22.30
(+16.1%)
Share & Embed Analysis
Last updated: October 23, 2026 12:29 AM ET
Data refreshes hourly during market hours. Next update: 1:29 AM
Data refreshes hourly during market hours. Next update: 1:29 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
28 analysts |
$92 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 68 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 77 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 49 HOLD |
